Forty Seven to Present at Upcoming Investor Conferences in February
- Guggenheim Healthcare Talks | Oncology Day on
Thursday, February 13, 2020at 11:30 a.m. ETin New York, NY.
- 9th Annual
SVB Leerink Global Healthcare Conferenceon Tuesday, February 25, 2020at 11:30 a.m. ETin New York, NY.
A live webcast of each presentation will be available under “Events & Presentations” in the Investors section of Forty Seven’s website at www.fortyseveninc.com. A replay of the webcasts will be available on Forty Seven’s website for 90 days following each presentation.
About Forty Seven, Inc.
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. Forty Seven’s lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia and non-Hodgkin’s lymphoma.
For journalist enquiries please contact
For investor enquiries please contact
Source: Forty Seven, Inc.